Transforming Stroke Recovery with Neuromodulation | Rigu Gupta, PiroGon | MTW North America 2026

Why It Matters

By replacing invasive implants with a non‑invasive, AI‑controlled neuromodulation device, Paragon could dramatically lower mortality from aspiration pneumonia and set a new standard for personalized neuro‑rehabilitation.

Key Takeaways

• Paragon offers non‑invasive neuromodulation technology via natural‑orifice delivery.
• Targets stroke‑related dysphagia and aspiration‑induced pneumonia in patients.
• Clinical data shows 60% recover swallowing within three days.
• FDA submission planned early next year, market entry aimed for 2028.
• AI-driven closed‑loop system provides real‑time personalized therapy feedback.

Summary

At MedTech World in Miami, Paragon unveiled a non‑surgical neuromodulation platform that is delivered through a natural orifice—typically the nasal passage—mirroring the simplicity of a feeding tube. The company’s focus is on improving pulmonary health, specifically treating dysphagia and aspiration‑related pneumonia in stroke survivors and sedated patients.

The technology avoids the risks of traditional brain or spinal implants by using micro‑joule, micro‑amp stimulation, dramatically lowering complication rates. Paragon reports that 60% of stroke patients regain swallowing function within three days, with an additional 20‑30% recovering in five days, addressing a condition that contributes to roughly 200,000 U.S. deaths annually.

Rigu Gupta emphasized the closed‑loop nature of the system: AI‑driven deep‑learning algorithms interpret sensor feedback in real time, allowing precise, personalized dosing without the side‑effects typical of pharmaceuticals. He noted, “We give microjoules, very microamps—patients don’t feel it,” underscoring the minimal sensory impact.

The firm is finalizing its design freeze and preparing an FDA submission early next year, targeting market availability by 2028. Successful clearance could reshape care for vulnerable neurological patients, reduce invasive surgeries, and open a broader pipeline for peripheral neuro‑disorder therapies.

Original Description

Rigu Gupta, Founder and CEO of PiroGon, joins Logan Plaster in the Media Lounge at MedTech World North America 2026 to discuss the company’s non-invasive neuromodulation platform and its potential to support patients with neurological and pulmonary conditions.

Unlike traditional neuromodulation systems that often require invasive surgical procedures, PiroGon is developing a platform designed to deliver therapy through natural pathways, reducing procedural risks while expanding access to treatment.

In this interview, Rigu discusses:

• What neuromodulation is and how it is used in healthcare

• The limitations of traditional implant-based approaches

• Developing non-invasive therapies for stroke recovery and swallowing disorders

• Addressing complications associated with aspiration and pneumonia

• The role of AI and machine learning in neuromodulation systems

• Creating feedback-driven therapies that connect biology and technology

• PiroGon’s FDA submission plans and product pipeline

Recorded at MedTech World North America, held at the Hilton West Palm Beach, Florida, from 11–13 May 2026.

Subscribe for more conversations with MedTech founders, investors, healthcare leaders, and innovators from around the world.

#MedTechWorld #MedTechWorldNorthAmerica2026 #MedTech #Neuromodulation #MedicalDevices #StrokeRecovery #HealthcareInnovation #ArtificialIntelligence #MedicalTechnology #DigitalHealth #HealthTech #FDA #MedicalDeviceStartup #PiroGon #WestPalmBeach #MTWNorthAmerica "